Neuberger Berman Group
KALV

Neuberger Berman Group’s KalVista Pharmaceuticals KALV Stock Holding History

Neuberger Berman Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-58,812
Closed -$682K – 1564
2019
Q3 		$682K Sell
58,812
-5,588
-9% -$90.3K ﹤0.01% 1217
2019
Q2 		$1.43M Buy
64,400
+30,900
+92% +$725K ﹤0.01% 1097
2019
Q1 		$959K Buy
+33,500
New +$726K ﹤0.01% 1126

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Neuberger Berman Group's KALV Position: Q4 2019 in Review

Neuberger Berman Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2019, closing a stake of 58,812 shares — an estimated $682K sold.

Neuberger Berman Group first reported a position in KALV in Q1 2019 and held it in 3 quarters. The position peaked at $1.43M in Q2 2019. 73 funds tracked by Wall St. Rank hold KALV as of Q4 2019.

  • Neuberger Berman Group reported no remaining KalVista Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Neuberger Berman Group sold 58,812 KalVista Pharmaceuticals shares in Q4 2019, an estimated $682K.
  • Neuberger Berman Group first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Neuberger Berman Group's KalVista Pharmaceuticals position peaked at $1.43M in Q2 2019.
  • 73 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2019.

Based on Neuberger Berman Group's 13F filing for Q4 2019, filed 12 Feb 2020.